Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Matsui K, Miyawaki Y, Suzuki Y, Furube T, Yoshizawa M, Toriumi T, Ebara G, Sato H, Sakuramoto S. Relationship between immune-related adverse events and long-term survival in patients treated with immune checkpoint inhibitors for unresectable advanced or recurrent esophageal cancer. Dis Esophagus. 2026 Mar 02; 39(2).
-
Manca ML, Michelangeli A, Bocci G, Orlandi P, Allegrini G, Kirken RA, Francia G, Georgiev V. Mathematical analysis of metronomic chemotherapy response in metastatic gastrointestinal cancer: identifying critical parameters from clinical data. Sci Rep. 2026 Jan 11; 16(1):1571.
-
Chambers LM, Chalif J, Yao M, Reizes O, Rose PG, Michener CM, Vargas R. Gram-positive targeting antibiotics are associated with progression and death in women with platinum-sensitive recurrent high grade epithelial ovarian cancer. J Gynecol Oncol. 2026 01; 37(1):e69.
-
Barajas J, Yang Z, Agyare E, Zhu X, Yoon SJ, Han B. Matrix stiffness influences drug resistance to gemcitabine analog and AZD 1775 combination in PDAC organoids. PLoS One. 2025; 20(12):e0326550.
-
Cruz-Correa M, Oh DY, Kato K, Tabernero J, Bai Y, Shi J, Lee KW, Hirano H, Spigel D, Wyrwicz L, Pazo Cid R, Cubillo Graci?n A, Xu Y, Sheng T, Yang S, Xu RH, Moehler M. Tislelizumab?+?Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up. Adv Ther. 2026 Jan; 43(1):165-183.
-
Yoshizawa M, Miyawaki Y, Sato H, Kawasaki T, Furube T, Matsui K, Suzuki Y, Toriumi T, Kishimoto Y, Ebara G, Hirano Y, Okamoto K, Sakuramoto S. Esophageal Lymphoepithelioma-like Carcinoma With a Remarkable Response to DCF Chemotherapy: A Case Report. Anticancer Res. 2025 Oct; 45(10):4643-4652.
-
Brim H, Gonzales S, Deverapalli M, Laiyemo AO, Rashid M, Zafar R, Nembhard C, Ashktorab H. Advanced-stage colorectal cancer in the context of coronavirus disease-19, highlighting socioeconomic disparities and outcomes: a case report. J Med Case Rep. 2025 Sep 29; 19(1):467.
-
Matsuo K, Enserro DM, Wright JD, Roman LD, Powell MA, Miller DS, Nagel CI, Thaker PH, Mannel RS, Stuckey AR, Guntupalli SR, Sukumvanich P, Geller MA, Vargas R, Konecny GE, Warshal DP, Tewari KS, Spirtos NM, Pothuri B, Creasman WT, Mutch DG. Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol. 2025 10; 201:184-194.
-
Patel R, Fukui J, Klein P, Moshier E, Kocyigit H, Fiedler L, Bucwinska W, Xing XY, Shapiro C, Goel A, Fasano J, Shao T, Bhardwaj A, Kim E, Vaccaro R, Lee K, Wilck E, Tiersten A. Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer. Breast Cancer Res Treat. 2025 Nov; 214(2):159-170.
-
Matsui K, Miyawaki Y, Kobayashi R, Yoshizawa M, Toriumi T, Ebara G, Sato H, Sakuramoto S. Clinical advantages of two vs. three courses of neoadjuvant chemotherapy using docetaxel?+?cisplatin?+?5-fluorouracil to improve preoperative nutritional status and mitigate decreasing skeletal muscle in resectable esophageal cancer. Int J Clin Oncol. 2025 Oct; 30(10):1992-2002.